Abstract
Once overlooked, awareness of nontuberculous mycobacterial pulmonary disease (NTM-PD) is rapidly rising, in line with increasing prevalence worldwide. The European Respiratory Society (ERS) International Congress 2019, held in Madrid, Spain, provided a platform for invigorating discussions and exciting new research in the field. This article explores approaches being taken to combat NTM-PD with a focus not only on novel prevalence and risk factor data, but also on emerging antimicrobials and their routes of delivery, and other potential treatment options in early clinical development.
Publisher
European Respiratory Society (ERS)
Subject
Pulmonary and Respiratory Medicine
Reference60 articles.
1. FDA . The voice of the patient. Non-tuberculous mycobacterial lung infection. Public meeting: October 15, 2015; Report date April 2016. www.fda.gov/media/96932/download Date last accessed: February 2020.
2. Nontuberculous Pulmonary Mycobacteriosis in Denmark
3. Predictors of 5-year mortality in pulmonary Mycobacterium avium-intracellulare complex disease
4. Mortality after respiratory isolation of nontuberculous mycobacteria. A comparison of patients who did and did not meet disease criteria;Novosad;Ann Am Thorac Soc,2017
5. Pulmonary nontuberculous mycobacteria-associated deaths, Ontario, Canada, 2001–2013;Marras;Emerging Infect Dis,2017
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献